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Recent studies have found an association between functional variants in TREM2 and PLD3 and 
Alzheimer’s disease (AD), but their effect on cognitive function is unknown. We examined the 
effect of these variants on cognitive function in 1,449 participants from the Wisconsin Registry 
for Alzheimer’s Prevention, a longitudinal study of initially asymptomatic adults, age 36-73 at 
baseline, enriched for a parental history of AD. A comprehensive cognitive test battery was 
performed at up to five visits. A factor analysis resulted in six cognitive factors that were 
standardized into z scores (~N [0, 1]); the mean of these z scores was also calculated. In linear 
mixed models adjusted for age, gender, practice effects, and self-reported race/ethnicity, PLD3 
V232M carriers had significantly lower mean z scores (p=0.02), and lower z scores for Story 
Recall (p=0.04), Visual Learning & Memory (p=0.049), and Speed & Flexibility (p=0.02) than 
non-carriers. TREM2 R47H carriers had marginally lower z scores for Speed & Flexibility 
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(p=0.06).  In conclusion, a functional variant in PLD3 was associated with significantly lower 
cognitive function in individuals carrying the variant than in non-carriers. 
 




Alzheimer’s disease (AD) is the most common form of dementia, accounting for 60-80% of 
dementia cases. Over 5 million Americans have AD and that number is expected to increase to 
nearly 14 million by 2050 due to the projected increase in the number of older Americans 
(Alzheimer's Association, 2016). AD is the sixth leading cause of death in the United States and 
the only of the top ten causes of death with no way to prevent, cure, or impede its progression 
(Alzheimer's Association, 2013). There are currently few known risk factors that are highly 
predictive of AD. Individuals with a family history of AD are known to be at increased risk for 
developing the disease, and the 4 allele of the apolipoprotein E gene (APOE) is also a well-
established risk factor. Carrying one copy of the APOE 4 allele results in a three-fold higher 
risk of developing AD than those with two copies of the more common 3 allele, and those with 
two copies of the 4 allele have an 8- to 12-fold higher risk (Holtzman, et al., 2012,Loy, et al., 
2014).  
Recent genome-wide association studies (GWAS) have identified 19 additional genetic 
regions that are associated with AD (Lambert, et al., 2013,Naj, et al., 2011). While potentially 
important for risk prediction, the genetic variants in these regions are of unknown function and 
have modest odds ratios (OR) ranging from 1.1 to 1.2 per risk allele. Moreover, these variants 
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together explain a relatively small portion of the full genetic contribution to AD (Ridge, et al., 
2013). GWAS have typically focused on common genetic variants, with minor allele frequencies 
5%, as these were historically the types of variants included on genome-wide chips. However, 
recent sequencing studies have identified three functional low frequency (minor allele frequency 
0.5-5%) variants with a more substantial effect (OR of approximately 2-5) on risk for AD: R47H 
in the triggering receptor expressed on myeloid cells 2 gene (TREM2) [(Guerreiro, et al., 
2012);(Jonsson, et al., 2012)], and V232M and A442A (splice site variant) in the phospholipase 
D family, member 3 gene (PLD3) (Cruchaga, et al., 2013). We sought to examine the effect of 
these variants on cognitive performance in a longitudinal study of middle-aged adults who were 
cognitively healthy at enrollment and enriched for a parental history of AD.  
 
2. Methods 
2.1. Study population 
Study participants were from the Wisconsin Registry for Alzheimer’s Prevention (WRAP), a 
longitudinal study of initially asymptomatic adults, age 36-73 at baseline, that allows for the 
enrollment of siblings and is enriched for a parental history of AD (i.e., a biological parent with 
either autopsy-confirmed AD, probable AD as defined by NINCDS-ADRDA research criteria 
(McKhann, et al., 1984), or dementia due to AD based on the Dementia Questionnaire (DQ) 
(Ellis, et al., 1998)). Details of the study design and methods have been previously described 
(Engelman, et al., 2014,La Rue, et al., 2008,Sager, et al., 2005). Baseline recruitment began in 
2001 with initial follow up after four years and subsequent ongoing follow up every two years or 
until a participant receives a clinical diagnosis of AD, at which point they are no longer 
followed. Data from up to five study visits were available for the current analyses. A total of 
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1,449 WRAP participants had genotypic data for the low frequency variants analyzed in the 
current study. This study was conducted with the approval of the University of Wisconsin 
Institutional Review Board and all subjects provided signed informed consent before 
participation. 
2.2. Neuropsychological assessment 
The WRAP cognitive test battery assesses many domains and has been previously described 
(Darst, et al., 2015,Sager, et al., 2005). For these analyses, we used one composite variable 
estimating cognitive functioning at age 54 (the mean age at baseline) and six factor scores 
representing longitudinal functioning across memory and executive function domains.  
2.2.1. Composite Progression Score 
A composite index, named progression score (PS), was computed using a set of eight cognitive 
measures, including Trails A and B (Reitan and Wolfson, 1985), Digit Span Forward and Digit 
Span Backward (Wechsler, 1997), Rey Auditory Verbal Learning Test (AVLT) summed score 
across five learning trials (Lezak, et al., 2004), AVLT delayed recall (Lezak, et al., 2004), 
Boston Naming Test (Kaplan, et al., 1983), and the Mini-Mental State Examination (Folstein, et 
al., 1975). Visits with fewer than four of these measurements were excluded. We applied the PS 
model (Bilgel, et al., 2015,Jedynak, et al., 2012) to align individuals along a linear cognitive 
trajectory based on their longitudinal cognitive measure profiles, adjusting for inter-individual 
differences in rates of change, with a higher PS indicating greater overall cognitive decline 
across the eight measures. We accounted for correlations among cognitive measures and 
constrained the progression scores to increase linearly with age within each individual. To 
remove confounding effects of age at entry into WRAP, the progression score was estimated at 
age 54, the mean age at baseline. 
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2.2.2. Longitudinal Factor Scores 
A factor analysis of the neuropsychological test scores was performed as described previously 
(Dowling, et al., 2010,Jonaitis, et al., 2015,Koscik, et al., 2014). The resulting factor scores were 
standardized into z scores (~N [0, 1]), using means and standard deviations obtained from the 
whole sample at baseline (visit 1) or visit 2 for a subset of tests that were first administered at 
this visit. There were four cognitive factor z scores for memory (Immediate Memory, Verbal 
Learning & Memory, Story Recall, and Visual Learning & Memory) and two for executive 
function (Working Memory and Speed & Flexibility). Tests comprising each of these factors 
have been previously described (Darst, et al., 2015).  Due to the small number of individuals 
carrying the functional variants, these six factor scores were also averaged to create a summary 
cognitive measure of the factor scores for each individual. Consequently, we did not adjust for 
multiple comparisons when examining the mean z score and used the individual cognitive factor 
scores to inform which domains were driving the association with the mean z score.  
2.3 DNA Collection, Genotyping, and Quality Control 
DNA was extracted from whole blood samples as described previously (Engelman, et al., 2013). 
Genotyping of the TREM2 variant R47H (rs75932628) and PLD3 variants V232M 
(rs145999145) and A442A (rs4819; splice site variant) was performed using competitive allele-
specific PCR based KASPTM genotyping assays (LGC Genomics, Beverly, MA). The quality 
control process has been described previously (Darst, et al., 2016). The PLD3 splice site variant, 
A442A, was monomorphic in our sample. Consequently, no genetic association analysis could 
be performed on this variant. The other PLD3 variant and the TREM2 variant were in Hardy-
Weinberg equilibrium. 
2.4. Statistical analysis 
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Differences in allele frequencies between those with a parental history of AD and those without 
were tested using a Fisher’s exact test. TREM2 and PLD3 associations with each of the cognitive 
factor scores and the PS at age 54 were tested using linear mixed models (SAS PROC MIXED) 
by comparing carriers of one of the rare variants to non-carriers of either. For each cognitive 
factor score, models included fixed effects for age, gender, practice effects, and self-reported 
race/ethnicity and random effects for family (siblings) and participant (repeated measures). For 
the PS, the model included fixed effects for gender and race/ethnicity (age was not adjusted for 
as it was used to calculate the PS) and a random effect for family. To visually display the 
cognitive factor z scores, adjusted mean z scores (a weighted average of the predicted z scores 
across all classes of gender and race/ethnicity, and for the average age) were calculated and 
plotted for TREM2 R47H and PLD3 V232M carriers, as well as for APOE 4 homozygotes, 4 
heterozygotes, and non-carriers of any of these three risk variants, using the LSMEANS 
statement in PROC MIXED with the OM option to weight the average of the predictions to be 
proportionate to the input data set.  This was especially important for race/ethnicity, which was 
not evenly distributed in the WRAP cohort. All analyses were performed in SAS v9.4 and used a 
p value threshold of < 0.05 to determine significance. 
 
3. Results 
Characteristics of the 1,449 participants, according to TREM2 and PLD3 carrier status, are 
shown in Table 1. No participants carried both the TREM2 R47H (T allele) and PLD3 V232M 
(A allele) low frequency variants. There were no significant (p < 0.05) differences in the 
characteristics between carriers of either variant and non-carriers.  Of the 16 participants who 
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carried the TREM2 variant, 15 were non-Hispanic Caucasian, 1 was Hispanic, and none were 
African American or another race/ethnicity. All 13 PLD3 carriers were non-Hispanic Caucasian. 
Presence of the TREM2 R47H variant was associated with AD parental history status; all 
sixteen participants with R47H were in the parental history group (Table 2). Patterns appeared 
similar for the relationship between PLD3 V232M and AD parental history. 
 In linear mixed models, PLD3 carriers had significantly lower mean z scores, and lower z 
scores for Story Recall, Visual Learning & Memory, and Speed & Flexibility than non-carriers 
(Table 3; results for APOE 4 count are shown for comparison). TREM2 carriers had marginally 
lower z scores for Speed & Flexibility (p = 0.06). While the PS at age 54 was higher for both 
TREM2 and PLD3 carriers, indicating greater disease progression, these differences were not 
statistically significant. Adjusted mean z scores for the six cognitive factors for TREM2 carriers, 
PLD3 carriers, as well as for APOE 4 homozygotes, 4 heterozygotes, and non-carriers of any 
of these three risk variants are shown in Figure 1.  
 
4. Discussion 
Functional low frequency variants in TREM2 are established risk factors for AD and an 
additional variant in PLD3 has been reported (Cruchaga, et al., 2013), but their effect on 
cognitive function in the years prior to the typical onset of AD is unknown. We examined the 
effect of these variants on cognitive performance in a longitudinal study of middle-aged adults 
who were cognitively healthy at enrollment, the majority of whom had a parental history of AD. 
The TREM2 R47H variant was found in 15 non-Hispanic Caucasians and 1 Hispanic, all with a 
parent who had AD. The PLD3 V232M variant was only found in non-Hispanic Caucasians and 
was twice as common in individuals with a parental history of AD than in those without a 
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parental history. Although both variants were generally associated with lower cognitive function 
in carriers of either variant than in non-carriers, only carriers of the PLD3 variant had 
significantly lower cognitive function than non-carriers. 
Our study population was intentionally enriched for individuals with a parental history of 
AD (72% of participants). While the carrier percentages in the parental history group were 1.5% 
for TREM2 R47H (T allele) and 1.1% for PLD3 V232M (A allele), the percentages in the 
participants with no parental history of AD were 0% and 0.5%, respectively. The TREM2 R47H 
carrier percentage is 0.4% in the Exome Aggregation Consortium database (ExAC; N = 60,145; 
accessed 11/15/16) (Lek, et al., 2016) and 0.5% in the Genome Aggregation Database (gnomAD; 
N = 140,485; beta mode available at http://gnomad.broadinstitute.org; accessed 11/15/16; 
includes samples from the Alzheimer’s Disease Sequencing Project and from ExAC). The PLD3 
V232M carrier percentage was 0.6% in ExAC (N = 57,683) and 0.7% in gnomAD (N = 
141,023). Taken together, for both variants, the percent of individuals carrying the low frequency 
risk variant was higher in WRAP participants with a parental history of AD than in WRAP 
participants without a family history or in publicly available reference databases, illustrating the 
statistical power to be gained from a study design focusing on individuals with a family history 
of AD, in which low frequency risk variants are likely to be more prevalent. 
 Our cohort is 89% non-Hispanic Caucasian, with only 113 African Americans and 34 
Hispanics, however, despite these small sample sizes, we did observe one Hispanic carrier of the 
TREM2 R47H variant. In gnomAD, the largest compilation of large-scale sequencing projects, 
the TREM2 R47H (T allele) was carried by 0.7% of Latinos (n = 18,221), 0.5% of Europeans 
(non-Finnish; n = 62,674), and 0.1% of Africans (n = 12,921). This higher carrier frequency in 
Latinos and lower carrier frequency in Africans is consistent with our observation. Moreover, 
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our lack of PLD3 V232M (A allele) carriers in any group other than non-Hispanic Caucasian is 
not surprising given that the carrier percentage in gnomAD for this variant is 2.5 to 5 times 
higher for Europeans (non-Finnish; 1%) than for Latinos (0.4%) or Africans (0.2%).    
PLD3 V232M carriers (six of whom were APOE 4 heterozygotes [Table 1]) had least 
square mean (predicted) cognitive z scores that were lower than both APOE 4 heterozygotes and 
homozygotes across all six cognitive factors (Figure 1). This suggests that the effect of the PLD3 
V232M variant on cognition may be even stronger than carrying two copies of the APOE 4 
allele. However, this requires replication in other longitudinal studies of cognitive function. 
Although our findings show consistency across multiple cognitive factors, many of our 
findings were not statistically significant, and those that were would not survive a correction for 
multiple testing. This is likely due to the rarity of the variants assessed, but could also be because 
our relatively young (early 50’s at baseline) population may not yet have experienced enough 
cognitive decline. It will be crucial to validate these findings with an external population, 
particularly one that has a larger number of carriers for these rare variants. Further, in order to 
determine how these variants influence the pathology of AD, it will also be essential to evaluate 
their influence on β-amyloid and tau, as the accumulation of both occurs long before an AD 
diagnosis.   
In conclusion, our results support previous findings that show an increased AD risk in 
carriers of low frequency functional variants in TREM2 and PLD3 by suggesting that these 
variants may also be associated with lower cognitive function, likely due to an AD trajectory. 
This is particularly notable for the rare PLD3 variant, which is a less established AD risk factor. 
While these functional variants are found at low frequencies in the population, their effect on risk 
for AD is much larger than common variants found through GWAS. In fact, their effect on 
© 2017. This manuscript version is made available under the CC-BY-NC-ND 4.0 license http://creativecommons.org/licenses/by-nc-nd/4.0/
 10 
cognition may be similar to, if not greater than, that of the APOE 4 allele. Further research is 
necessary in order to assess the influence of these rare variants on other crucial neurological 
changes such as the accumulation of β-amyloid and tau that are biomarkers of AD pathology. 
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Age (years) 52.4 (5.6) 51.8 (8.9) 53.8 (6.6) 
Gender (female) 13 (81.3) 10 (76.9) 898 (70.0) 
Race/ethnicity    
Caucasian 15 (93.8) 13 (100.0) 1,253 (88.8) 
African American 0 0 113 (8.0) 
Hispanic 1 (6.3) 0 33 (2.3) 
Other 0 0 12 (0.9) 
Years of Education 15.3 (2.8) 15.7 (3.1) 16.2 (2.3) 
APOE Genotype    
ε2/ε2 0 0 5 (0.4) 
ε2/ε3 1 (6.3) 3 (23.1) 113 (8.0) 
ε2/ε4 1 (6.3) 0 46 (3.3) 
ε3/ε3 6 (37.5) 4 (30.8) 742 (52.5) 
ε3/ε4 7 (43.8) 6 (46.2) 447 (31.6) 
ε4/ε4 1 (6.3) 0 60 (4.2) 
aNo participants carried both the TREM2 and PLD3 variants; seven participants had a 
missing genotype for either TREM2 or PLD3 and are not included in this table. Minor/risk 










Table 2. Carrier Frequency (n) by Parental History of AD 
Gene (variant) 
No parent with AD 
(n=409) 
Parent with AD 
(n=1040) p valuea 
TREM2 (R47H) 0.00 (0) 0.015 (16) 0.009 
PLD3 (V232M) 0.005 (2) 0.011 (11) 0.54 
aFisher’s exact test of the difference in allele frequency in individuals without versus with 
a parent with AD. 
© 2017. This manuscript version is made available under the CC-BY-NC-ND 4.0 license http://creativecommons.org/licenses/by-nc-nd/4.0/
 16 
Table 3.  Association Between Risk Variant and Cognitive Function 
Cognitive Function 





APOE ε4 count 
Composite Progression Score    
  Progression Score at age 54a 0.19 ± 0.29 (0.52) 0.46 ± 0.33 (0.16) 0.11 ± 0.05 (0.04) 
Longitudinal Factor Scores    
  Mean of six Factor Scores -0.14 ± 0.16 (0.38) -0.41 ± 0.18 (0.02) -0.10 ± 0.03 (0.002) 
  Immediate Memory -0.12 ± 0.20 (0.56) -0.23 ± 0.23 (0.32) -0.07 ± 0.04 (0.06) 
  Verbal Learning & Memory -0.002 ± 0.22 (0.99) -0.22 ± 0.25 (0.37) -0.09 ± 0.04 (0.03) 
  Story Recall -0.16 ± 0.24 (0.49) -0.55 ± 0.26 (0.04) -0.14 ± 0.05 (0.002) 
  Visual Learning & Memory -0.06 ± 0.22 (0.78) -0.49 ± 0.25 (0.049) -0.08 ± 0.04 (0.05) 
  Working Memory -0.15 ± 0.23 (0.51) -0.26 ± 0.27 (0.34) -0.11 ± 0.04 (0.01) 
  Speed & Flexibility -0.39 ± 0.20 (0.06) -0.54 ± 0.24 (0.02) -0.06 ± 0.04 (0.11) 
Linear mixed model, adjusting for age, gender, practice effects, and race/ethnicity, and accounting for 
within-family (sibling) correlations and within-individual correlations from up to 10 years of follow up. 
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Figure 1. Mean Adjusted Cognitive Function by Risk Allele Carrier Status. Adjusted (for 
age, gender, practice effects, and race/ethnicity) mean z scores for the six cognitive factors for 
TREM2 R47H (T allele) carriers (light gray), PLD3 V232M (A allele) carriers (medium gray), 
APOE 4 heterozygotes (dark gray), APOE 4 homozygotes (very dark gray), and non-carriers of 
any of these three risk variants (white). Z scores were standardized (~N [0, 1]), using means and 
standard deviations obtained from the whole sample at baseline. Error bars indicate standard 
error of the mean. 
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